Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID‐19
Abstract The broad immunomodulatory properties of human mesenchymal stem cells (MSCs) have allowed for wide application in regenerative medicine as well as immune/inflammatory diseases, including unmatched allogeneic use. The novel coronavirus disease COVID‐19 has unleashed a pandemic in record time...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Oxford University Press
2020-10-01
|
| Series: | Stem Cells Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/sctm.20-0186 |
| _version_ | 1819109250459238400 |
|---|---|
| author | B. Linju Yen Men‐Luh Yen Li‐Tzu Wang Ko‐Jiunn Liu Huey‐Kang Sytwu |
| author_facet | B. Linju Yen Men‐Luh Yen Li‐Tzu Wang Ko‐Jiunn Liu Huey‐Kang Sytwu |
| author_sort | B. Linju Yen |
| collection | DOAJ |
| description | Abstract The broad immunomodulatory properties of human mesenchymal stem cells (MSCs) have allowed for wide application in regenerative medicine as well as immune/inflammatory diseases, including unmatched allogeneic use. The novel coronavirus disease COVID‐19 has unleashed a pandemic in record time accompanied by an alarming mortality rate mainly due to pulmonary injury and acute respiratory distress syndrome. Because there are no effective preventive or curative therapies currently, MSC therapy (MSCT) has emerged as a possible candidate despite the lack of preclinical data of MSCs for COVID‐19. Interestingly, MSCT preclinical data specifically on immune/inflammatory disorders of the lungs were among the earliest to be reported in 2003, with the first clinical use of MSCT for graft‐vs‐host disease reported in 2004. Since these first reports, preclinical data showing beneficial effects of MSC immunomodulation have accumulated substantially, and as a consequence, over a third of MSCT clinical trials now target immune/inflammatory diseases. There is much preclinical evidence for MSCT in noninfectious—including chronic obstructive pulmonary disease, asthma, and idiopathic pulmonary fibrosis—as well as infectious bacterial immune/inflammatory lung disorders, with data generally demonstrating therapeutic effects; however, for infectious viral pulmonary conditions, the preclinical evidence is more scarce with some inconsistent outcomes. In this article, we review the mechanistic evidence for clinical use of MSCs in pulmonary immune/inflammatory disorders, and survey the ongoing clinical trials—including for COVID‐19—of MSCT for these diseases, with some perspectives and comment on MSCT for COVID‐19. |
| first_indexed | 2024-12-22T03:22:50Z |
| format | Article |
| id | doaj.art-de7e5afe08ff4c3a8cf90b32e606c19f |
| institution | Directory Open Access Journal |
| issn | 2157-6564 2157-6580 |
| language | English |
| last_indexed | 2024-12-22T03:22:50Z |
| publishDate | 2020-10-01 |
| publisher | Oxford University Press |
| record_format | Article |
| series | Stem Cells Translational Medicine |
| spelling | doaj.art-de7e5afe08ff4c3a8cf90b32e606c19f2022-12-21T18:40:41ZengOxford University PressStem Cells Translational Medicine2157-65642157-65802020-10-019101163117310.1002/sctm.20-0186Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID‐19B. Linju Yen0Men‐Luh Yen1Li‐Tzu Wang2Ko‐Jiunn Liu3Huey‐Kang Sytwu4Regenerative Medicine Research Group Institute of Cellular & System Medicine, National Health Research Institutes (NHRI) Zhunan TaiwanDepartment of Obstetrics/Gynecology National Taiwan University (NTU) Hospital & College of Medicine, NTU Taipei TaiwanDepartment of Obstetrics/Gynecology National Taiwan University (NTU) Hospital & College of Medicine, NTU Taipei TaiwanNational Institute of Cancer Research, NHRI Tainan TaiwanNational Institute of Infectious Diseases & Vaccinology, NHRI Zhunan TaiwanAbstract The broad immunomodulatory properties of human mesenchymal stem cells (MSCs) have allowed for wide application in regenerative medicine as well as immune/inflammatory diseases, including unmatched allogeneic use. The novel coronavirus disease COVID‐19 has unleashed a pandemic in record time accompanied by an alarming mortality rate mainly due to pulmonary injury and acute respiratory distress syndrome. Because there are no effective preventive or curative therapies currently, MSC therapy (MSCT) has emerged as a possible candidate despite the lack of preclinical data of MSCs for COVID‐19. Interestingly, MSCT preclinical data specifically on immune/inflammatory disorders of the lungs were among the earliest to be reported in 2003, with the first clinical use of MSCT for graft‐vs‐host disease reported in 2004. Since these first reports, preclinical data showing beneficial effects of MSC immunomodulation have accumulated substantially, and as a consequence, over a third of MSCT clinical trials now target immune/inflammatory diseases. There is much preclinical evidence for MSCT in noninfectious—including chronic obstructive pulmonary disease, asthma, and idiopathic pulmonary fibrosis—as well as infectious bacterial immune/inflammatory lung disorders, with data generally demonstrating therapeutic effects; however, for infectious viral pulmonary conditions, the preclinical evidence is more scarce with some inconsistent outcomes. In this article, we review the mechanistic evidence for clinical use of MSCs in pulmonary immune/inflammatory disorders, and survey the ongoing clinical trials—including for COVID‐19—of MSCT for these diseases, with some perspectives and comment on MSCT for COVID‐19.https://doi.org/10.1002/sctm.20-0186ARDSasthmabacterial pneumoniaclinical trialCOPDCOVID‐19 |
| spellingShingle | B. Linju Yen Men‐Luh Yen Li‐Tzu Wang Ko‐Jiunn Liu Huey‐Kang Sytwu Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID‐19 Stem Cells Translational Medicine ARDS asthma bacterial pneumonia clinical trial COPD COVID‐19 |
| title | Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID‐19 |
| title_full | Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID‐19 |
| title_fullStr | Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID‐19 |
| title_full_unstemmed | Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID‐19 |
| title_short | Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID‐19 |
| title_sort | current status of mesenchymal stem cell therapy for immune inflammatory lung disorders gleaning insights for possible use in covid 19 |
| topic | ARDS asthma bacterial pneumonia clinical trial COPD COVID‐19 |
| url | https://doi.org/10.1002/sctm.20-0186 |
| work_keys_str_mv | AT blinjuyen currentstatusofmesenchymalstemcelltherapyforimmuneinflammatorylungdisordersgleaninginsightsforpossibleuseincovid19 AT menluhyen currentstatusofmesenchymalstemcelltherapyforimmuneinflammatorylungdisordersgleaninginsightsforpossibleuseincovid19 AT litzuwang currentstatusofmesenchymalstemcelltherapyforimmuneinflammatorylungdisordersgleaninginsightsforpossibleuseincovid19 AT kojiunnliu currentstatusofmesenchymalstemcelltherapyforimmuneinflammatorylungdisordersgleaninginsightsforpossibleuseincovid19 AT hueykangsytwu currentstatusofmesenchymalstemcelltherapyforimmuneinflammatorylungdisordersgleaninginsightsforpossibleuseincovid19 |